Phase 3 Maintenance Results Show Patients with Crohn s Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopic Response and Clinical Remission at One Year
- In Crohn s disease patients with clinical response to risankizumab IV induction treatment, a significantly greater proportion of patients treated with risankizumab 360 mg SC achieved endoscopic response and clinical remission at one year (52 weeks) versus those who were withdrawn from risankizumab (control group)[1]
- The overall safety results in this study were generally consistent with the known safety profile of risankizumab, with no new safety risks observed[1-7]
- Risankizumab (SKYRIZI), an interleukin-23 (IL-23) inhibitor, is being evaluated as a treatment for adults with moderate to severe Crohn s disease and several other immune-mediated conditions[1,8-10]
ABBVie today announced positive top-line results from the Phase 3 maintenance study, FORTIFY, showing risankizumab 360 mg achieved the co-primary endpoints of endoscopic response and clinical remission at one year in adult patients with moderate to severe Crohn's disease. 1 In this study, patients who responded to 12 weeks of risankizumab intravenous induction treatment were re-randomized to receive risankizumab 180 .
Ministry of Health and Family Welfare of the[ ] (via Public) / Dr Harsh Vardhan leads pledge to keep away from Tobacco on World No Tobacco Day 2021 publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.
Read more about Smokers face 40-50% higher risk of severe diseases, Covid death: Vardhan on Business Standard. Smokers face a 40-50 per cent higher risk of severe diseases and death from Covid-19, Union Health Minister Harsh Vardhan said on Monday
OECD Ministers have endorsed a new initiative to promote safe international travel during the COVID-19 pandemic at the OECD’s annual Ministerial meeting in Paris. The Initiative involves a safe travel blueprint and a temporary international cross-sectoral forum for knowledge sharing. The forum will allow governments and stakeholders to share information in real time on plans and approaches facilitating travel. The blueprint promotes greater certainty, safety and security in travel as re-opening takes place. It builds on existing initiatives and aims to increase interoperability amongst travel regimes. It will be implemented by countries on a voluntary basis.